NASDAQ Approves Cardiome Pharma Corp.'s Request to Transfer Its Listing to the NASDAQ Capital Market
Published: Oct 26, 2012
VANCOUVER, Canada, Oct. 25, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (TSX:COM) (Nasdaq:CRME) announced today that the NASDAQ Listing Qualifications Staff has approved the Company's request to transfer its listing from The NASDAQ Global Market to The NASDAQ Capital Market. Accordingly, the Company's common shares will begin trading on The NASDAQ Capital Market effective with the open of business on Friday, October 26, 2012. The transfer of the Company's listing should have no impact on trading in the Company's common shares, and the Company's common shares will continue to trade under the symbol CRME. In addition, the transfer will not impact the Company's listing on the Toronto Stock Exchange.